Emerging Insights into Neurodegeneration: A Proteomics Perspective
Neurodegenerative disorders such as Alzheimer’s, Parkinson’s and multiple sclerosis are rising, with cases projected to double over the next 20 years. While genetic risk factors like the APOE4 variant are associated with disease, genetics alone are insufficient. Nearly 40% of APOE4 homozygotes remain unaffected, underscoring the role of post genomic factors, including proteomic and immune system changes.
In this white paper, we explore how high-plex proteomics is opening new windows into disease biology. These protein biomarkers are proving critical not only for early detection, but also for tracking disease progression, distinguishing molecular subtypes and informing therapeutic decisions.
Get your free copy
Fill out the form to access the full white paper and explore how cutting-edge proteomics is reshaping our understanding of disease progression, subtypes and treatment response in neurodegenerative diseases.
White paper highlights:
- Understand the key molecular mechanisms driving neurodegenerative diseases
- Explore how therapies are evolving to target root causes rather than just symptoms
- See how high-dimensional proteomics is uncovering new biological insights in Alzheimer’s and Parkinson’s disease